Oppenheimer Notes Billing Confusion Impacting Inspire Medical
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy INSP?
Oppenheimer notes that earlier Thursday morning, the Wisconsin Physicians Service Medicare Administrative Contractor updated its hypoglossal nerve stimulation Local Coverage Determination to state that physicians should "use modifier 52 with CPT 64582 to bill at a reduced rate for professional services when billing for implantation without the insertion of a distal respiratory sensor." The firm believes this will lead to further confusion within Medicare billing as Inspire Medical has stated to use Current Procedural Terminology code 64582 without the 52 modifier. Oppenheimer had previously written that there may be problems if both i4 and i5 were being billed using the same code without the modifier due to differences in respective relative value units. It is unclear if/when other MACs may follow suit, but having a difference between respective jurisdictions will likely create another headache for Perform-rated Inspire.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INSP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INSP
Wall Street analysts forecast INSP stock price to rise
19 Analyst Rating
13 Buy
6 Hold
0 Sell
Moderate Buy
Current: 44.260
Low
91.00
Averages
145.31
High
180.00
Current: 44.260
Low
91.00
Averages
145.31
High
180.00
About INSP
Inspire Medical Systems, Inc. is a medical technology company. The Company focuses on the development and commercialization of advanced, minimally invasive solutions for patients with obstructive sleep apnea (OSA). Its proprietary Inspire therapy is neurostimulation technology that provides safe and effective treatment for moderate to severe obstructive sleep apnea. The Company's closed-loop solution continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The Company sells its Inspire system to hospitals and ambulatory surgery centers (ASCs) in the United States (U.S.) and in select countries in Europe and Japan through a direct sales organization and sells its Inspire system in Singapore and Hong Kong through distributors. Its direct sales force engages in sales efforts and promotional activities focused on ear, nose and throat (ENT) physicians and sleep centers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Inspire Medical Systems Q1 2026 Results and Guidance Revision
- Sales Performance Overview: Inspire Medical Systems reported Q1 2026 sales of $204.58 million, despite a net loss of $11.29 million, indicating pressure on the company's market competitiveness and profitability challenges.
- Guidance Revision: The company revised its full-year 2026 revenue guidance down to $825 million to $875 million, with diluted EPS adjusted to $0.07 to $0.62, reflecting negative impacts from reimbursement and coding issues that may dampen investor confidence.
- Shareholder Approval Plans: Inspire filed a $118.82 million shelf registration for 2.6 million common shares tied to its employee stock ownership plan and secured shareholder approval to expand its incentive award plan, highlighting ongoing investments in governance reforms and employee alignment.
- Long-Term Investment Outlook: Despite short-term reimbursement pressures, Inspire projects $1.1 billion in revenue and $97.5 million in earnings by 2029, requiring an 8% annual growth rate, indicating confidence in long-term market potential while cautioning against pessimistic market expectations.
See More
U.S. Stocks Close Higher, Led by Tech Gains
- Tech Stock Surge: Intel's stock soared over 12% after Apple held exploratory talks with Intel and Samsung Electronics for U.S. processor production, indicating strong market confidence in tech stocks and driving gains across chipmakers.
- Oil Price Decline: WTI crude oil prices fell more than 3% as the ceasefire in the Middle East eased geopolitical risks, providing support for the stock market and reflecting market demand for stability amid fluctuating oil prices.
- New Home Sales Growth: U.S. March new home sales rose 7.4% month-over-month to 682,000, surpassing expectations of 652,000, indicating a robust recovery in the housing market that could bolster economic confidence.
- Positive Earnings Outlook: As of Tuesday, 83% of the 354 S&P 500 companies that reported Q1 earnings exceeded estimates, with projected earnings growth of 12% year-over-year, demonstrating sustained corporate profitability that may further drive stock market gains.
See More
US Stocks Rise, Nasdaq Hits All-Time High
- Nasdaq Milestone: The Nasdaq 100 index surged by 1.20%, reaching an all-time high, driven by robust performance in technology stocks, reflecting increased investor confidence in the tech sector's growth potential.
- Intel's Strong Surge: Intel's stock rose over 13%, leading chipmakers after Apple indicated exploratory discussions with Intel and Samsung to produce key processors in the US, which is expected to enhance Intel's market share and profitability.
- Economic Data Impact: March new home sales in the US rose by 7.4% month-over-month to 682,000 units, surpassing expectations and indicating signs of recovery in the housing market, while the April ISM services index fell slightly below expectations, highlighting the complexities of economic recovery that may influence future monetary policy.
- Crude Oil Price Drop: WTI crude oil prices fell by more than 4% as calm returned to the Middle East, easing geopolitical risks, which is expected to positively impact inflation expectations and provide support for the stock market.
See More
U.S. Stocks Rise, Nasdaq Hits All-Time High
- Nasdaq Milestone: The Nasdaq 100 index rose by 1.08%, reaching an all-time high, driven by strong performances in technology stocks, particularly Intel, which surged over 10%, indicating increased market confidence in the tech sector.
- Crude Oil Decline: WTI crude prices fell by more than 3% as calm returned to the Middle East, despite U.S. Central Command's announcement of military support for ships transiting the Strait of Hormuz, which could impact global energy supply dynamics.
- Widening Trade Deficit: The U.S. trade deficit widened to $60.3 billion in March from $57.8 billion in February, although it was narrower than the expected $61 billion, reflecting the complexities of economic recovery and its potential implications for the stock market.
- Strong Earnings Reports: So far, 82% of the 322 S&P 500 companies that reported Q1 earnings have exceeded estimates, with overall earnings projected to rise by 12% year-over-year, indicating improved corporate profitability that may further drive stock market gains.
See More
Inspire Medical Systems Reports Q1 Loss, Lowers 2026 Guidance
- Financial Performance Decline: Inspire Medical Systems reported a net loss of $11.29 million for Q1 2026, translating to a loss of $0.39 per share, a stark contrast to last year's net income of $2.99 million or $0.10 per share, indicating severe financial challenges ahead for the company.
- Revenue Growth Stagnation: Although Q1 revenue increased by 1.6% to $204.58 million year-over-year, this growth was insufficient to offset the negative impacts from reimbursement and CPT coding disruptions, leading to a more pessimistic outlook for the company's future.
- 2026 Guidance Revision: The company has lowered its revenue guidance for 2026 to between $825 million and $875 million, down from the previous expectation of $950 million to $1 billion, with adjusted EPS projections also significantly reduced, reflecting the harsh market conditions.
- Market Reaction: Following the earnings report, Inspire Medical Systems' stock plummeted over 22% in pre-market trading, currently at $42.51, highlighting investor concerns regarding the company's future profitability and diminished confidence in management's outlook.
See More
Inspire Medical Systems Q1 2026 Earnings Call Insights
- Revenue Growth and Outlook Adjustment: Inspire Medical Systems reported a 1.6% year-over-year revenue increase to $204.6 million in Q1 2026, despite facing approximately $20 million in adverse impacts, leading management to revise the full-year revenue outlook to a range of $825 million to $875 million, reflecting a cautious stance on market conditions.
- Profitability Outlook Decline: The adjusted operating margin is now expected to range from 2% to 4%, with diluted EPS projected between $0.07 and $0.62, indicating challenges in navigating coding and reimbursement uncertainties that may affect future investor confidence.
- Cash Flow and Financial Health: The company generated $12.8 million in operating cash flow for the quarter and maintains a strong balance sheet with $400 million in cash and investments, demonstrating financial flexibility amid a challenging market environment.
- Coding and Reimbursement Challenges: Management highlighted that coding uncertainty has negatively impacted patient numbers, with anticipated adverse effects increasing to $40 million to $50 million in Q2, underscoring the importance of improving reimbursement processes in the coming months.
See More
Inspire Medical Systems Q1 2026 Results and Guidance Revision
- Sales Performance Overview: Inspire Medical Systems reported Q1 2026 sales of $204.58 million, despite a net loss of $11.29 million, indicating pressure on the company's market competitiveness and profitability challenges.
- Guidance Revision: The company revised its full-year 2026 revenue guidance down to $825 million to $875 million, with diluted EPS adjusted to $0.07 to $0.62, reflecting negative impacts from reimbursement and coding issues that may dampen investor confidence.
- Shareholder Approval Plans: Inspire filed a $118.82 million shelf registration for 2.6 million common shares tied to its employee stock ownership plan and secured shareholder approval to expand its incentive award plan, highlighting ongoing investments in governance reforms and employee alignment.
- Long-Term Investment Outlook: Despite short-term reimbursement pressures, Inspire projects $1.1 billion in revenue and $97.5 million in earnings by 2029, requiring an 8% annual growth rate, indicating confidence in long-term market potential while cautioning against pessimistic market expectations.
See More
U.S. Stocks Close Higher, Led by Tech Gains
- Tech Stock Surge: Intel's stock soared over 12% after Apple held exploratory talks with Intel and Samsung Electronics for U.S. processor production, indicating strong market confidence in tech stocks and driving gains across chipmakers.
- Oil Price Decline: WTI crude oil prices fell more than 3% as the ceasefire in the Middle East eased geopolitical risks, providing support for the stock market and reflecting market demand for stability amid fluctuating oil prices.
- New Home Sales Growth: U.S. March new home sales rose 7.4% month-over-month to 682,000, surpassing expectations of 652,000, indicating a robust recovery in the housing market that could bolster economic confidence.
- Positive Earnings Outlook: As of Tuesday, 83% of the 354 S&P 500 companies that reported Q1 earnings exceeded estimates, with projected earnings growth of 12% year-over-year, demonstrating sustained corporate profitability that may further drive stock market gains.
See More
US Stocks Rise, Nasdaq Hits All-Time High
- Nasdaq Milestone: The Nasdaq 100 index surged by 1.20%, reaching an all-time high, driven by robust performance in technology stocks, reflecting increased investor confidence in the tech sector's growth potential.
- Intel's Strong Surge: Intel's stock rose over 13%, leading chipmakers after Apple indicated exploratory discussions with Intel and Samsung to produce key processors in the US, which is expected to enhance Intel's market share and profitability.
- Economic Data Impact: March new home sales in the US rose by 7.4% month-over-month to 682,000 units, surpassing expectations and indicating signs of recovery in the housing market, while the April ISM services index fell slightly below expectations, highlighting the complexities of economic recovery that may influence future monetary policy.
- Crude Oil Price Drop: WTI crude oil prices fell by more than 4% as calm returned to the Middle East, easing geopolitical risks, which is expected to positively impact inflation expectations and provide support for the stock market.
See More
U.S. Stocks Rise, Nasdaq Hits All-Time High
- Nasdaq Milestone: The Nasdaq 100 index rose by 1.08%, reaching an all-time high, driven by strong performances in technology stocks, particularly Intel, which surged over 10%, indicating increased market confidence in the tech sector.
- Crude Oil Decline: WTI crude prices fell by more than 3% as calm returned to the Middle East, despite U.S. Central Command's announcement of military support for ships transiting the Strait of Hormuz, which could impact global energy supply dynamics.
- Widening Trade Deficit: The U.S. trade deficit widened to $60.3 billion in March from $57.8 billion in February, although it was narrower than the expected $61 billion, reflecting the complexities of economic recovery and its potential implications for the stock market.
- Strong Earnings Reports: So far, 82% of the 322 S&P 500 companies that reported Q1 earnings have exceeded estimates, with overall earnings projected to rise by 12% year-over-year, indicating improved corporate profitability that may further drive stock market gains.
See More
Inspire Medical Systems Reports Q1 Loss, Lowers 2026 Guidance
- Financial Performance Decline: Inspire Medical Systems reported a net loss of $11.29 million for Q1 2026, translating to a loss of $0.39 per share, a stark contrast to last year's net income of $2.99 million or $0.10 per share, indicating severe financial challenges ahead for the company.
- Revenue Growth Stagnation: Although Q1 revenue increased by 1.6% to $204.58 million year-over-year, this growth was insufficient to offset the negative impacts from reimbursement and CPT coding disruptions, leading to a more pessimistic outlook for the company's future.
- 2026 Guidance Revision: The company has lowered its revenue guidance for 2026 to between $825 million and $875 million, down from the previous expectation of $950 million to $1 billion, with adjusted EPS projections also significantly reduced, reflecting the harsh market conditions.
- Market Reaction: Following the earnings report, Inspire Medical Systems' stock plummeted over 22% in pre-market trading, currently at $42.51, highlighting investor concerns regarding the company's future profitability and diminished confidence in management's outlook.
See More
Inspire Medical Systems Q1 2026 Earnings Call Insights
- Revenue Growth and Outlook Adjustment: Inspire Medical Systems reported a 1.6% year-over-year revenue increase to $204.6 million in Q1 2026, despite facing approximately $20 million in adverse impacts, leading management to revise the full-year revenue outlook to a range of $825 million to $875 million, reflecting a cautious stance on market conditions.
- Profitability Outlook Decline: The adjusted operating margin is now expected to range from 2% to 4%, with diluted EPS projected between $0.07 and $0.62, indicating challenges in navigating coding and reimbursement uncertainties that may affect future investor confidence.
- Cash Flow and Financial Health: The company generated $12.8 million in operating cash flow for the quarter and maintains a strong balance sheet with $400 million in cash and investments, demonstrating financial flexibility amid a challenging market environment.
- Coding and Reimbursement Challenges: Management highlighted that coding uncertainty has negatively impacted patient numbers, with anticipated adverse effects increasing to $40 million to $50 million in Q2, underscoring the importance of improving reimbursement processes in the coming months.
See More
